Between 2019 and 2023, antibiotic consumption in the EU increased by 1%, moving further away from the target of a 20% reduction by 2030. Although there have been reductions in certain infections, carbapenem-resistant Klebsiella pneumoniae infections have increased by almost 60%. The ECDC has launched patient stories to highlight the impact of AMR. More interventions are needed to combat AMR, focusing on infection prevention, prudent antibiotic use, and access to new treatments. To achieve the 2030 targets, urgent action is required. The ECDC continues to support Member States in addressing AMR gaps and strengthening capabilities.
Source link
Urgent action needed to combat AMR and achieve EU’s 2030 targets
